• GS967 and the Aging Heart: Translational Strategy

  2026-09-25

  A mechanistic and practical guide to using GS967 to investigate late sodium current, age-linked cardiac dysfunction, and arrhythmia phenotypes. Learn how pharmacological inhibition can complement genetic models and in vitro cardiac electrophysiology while keeping translational conclusions appropriately bounded.

• How Sodium Overload Executes NECSO Through Mitochondria

  2026-09-25

  The study links TRPM4-mediated sodium entry to mitochondrial ion imbalance, impaired energy metabolism, and the terminal events of NECSO. Its findings frame mitochondrial bioenergetics as a key part of sodium-overload necrosis and suggest how membrane-potential measurements can complement, but not replace, direct metabolic and cell-death readouts.

• EZ Cap™ Firefly Luciferase mRNA Assay Guide

  2026-09-24

  A scenario-driven guide to using EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, in reporter, delivery, and cell-based experiments. Learn how to handle the transcript, interpret luminescence alongside viability measurements, and assess mRNA options using practical specification checks.

• GS967: Cardiac Late Sodium Current Workflows

  2026-09-24

  Use GS967 to test how pathological late sodium influx contributes to prolonged repolarization, calcium-handling changes, and arrhythmia phenotypes. This practical guide connects aging-heart findings to concentration-controlled myocyte and isolated-heart experiments, with controls and troubleshooting to help interpret results.

• Fulvestrant (ICI 182,780) for ER-Positive Assays

  2026-09-23

  A practical guide to using Fulvestrant (ICI 182,780), SKU A1428, in ER-positive breast cancer experiments—from assay design and compound handling to interpreting MDM2 and viability results. It distinguishes product-reported parameters from workflow recommendations and highlights where evidence should not be extrapolated across models.

• HPF for Highly Reactive Oxygen Species Detection

  2026-09-23

  HPF converts hROS chemistry into a selective fluorescein signal, making it useful for separating hydroxyl radical and peroxynitrite activity from broader oxidative readouts. This guide applies hydroxyphenyl fluorescein to copper-based nanotherapy, photodynamic workflows, microscopy, plate assays, and flow cytometry while emphasizing controls that prevent overinterpretation.

• GW4064: Non-Steroidal FXR Agonist Research Guide

  2026-09-22

  GW4064 is a potent, selective non-steroidal FXR agonist for dissecting bile acid metabolism, cholesterol and triglyceride regulation, and FXR signaling. Its nanomolar receptor activity contrasts with limited aqueous solubility, UV-sensitive chemical stability, and predominantly research-use status.

• Foxp1–Notch Control of Valvular Calcification in CKD

  2026-09-22

  A 2026 Biochemical Pharmacology study identifies endothelial Foxp1 as a protective regulator of chronic kidney disease–associated valvular calcification. The work links Foxp1 to repression of Jagged-1/Notch signaling, reduced endothelial-to-mesenchymal transition, lower TGF-β1-mediated activation of valvular interstitial cells, and less inflammatory macrophage recruitment.

• Phosphatase Inhibitor Cocktail 2: Assay Workflows

  2026-09-21

  Protect phosphorylation-dependent biology from tissue harvest through Western blotting, co-immunoprecipitation, and kinase assays with a broad-spectrum 100X formulation. This workflow-focused guide shows how to preserve PI3K/AKT/PPARγ signals while avoiding common dilution, storage, and sample-handling errors.

• EZ Cap™ Cas9 mRNA (m1Ψ) for Reliable Editing

  2026-09-21

  Learn how EZ Cap™ Cas9 mRNA (m1Ψ), SKU R1014, can reduce upstream variability in CRISPR-Cas9 experiments that rely on viability, proliferation, or cytotoxicity readouts. This scenario-based guide connects Cap1 capping, m1Ψ modification, controlled handling, and electroporation evidence to practical assay design.

• ω-Agatoxin IVA TFA in Cav2.1 Research

  2026-09-20

  ω-Agatoxin IVA TFA enables concentration-aware dissection of Cav2.1-dependent calcium entry, synaptic release, and seizure circuitry. Its strongest use-case is a linked workflow that combines neuronal calcium current recording with EEG, behavioral controls, and apoptosis or BDNF measurements in an epilepsy animal model.

• Deferasirox Workflows for Iron-Stress Research

  2026-09-19

  Use Deferasirox as a controlled iron-chelation tool for iron overload models, cancer metabolism studies, and nutrient-stress assays. This practical guide connects concentration planning, oxygen-aware dosing, lysosomal readouts, and troubleshooting to the emerging TCF25–V-ATPase–ferritinophagy pathway.

• MEG3, NiO Nanoparticles, and Pulmonary Fibrosis

  2026-09-18

  Zhan et al. identify lncRNA MEG3 as a regulatory brake on nickel oxide nanoparticle-induced pulmonary fibrosis, linking MEG3 loss to TGF-β1 activation and PI3K/AKT-dependent collagen formation. By combining a rat exposure model, A549 cell experiments, pharmacologic inhibition, and MEG3 overexpression, the study provides a mechanistic framework for investigating toxicant-driven fibrotic remodeling.

• GS967 and Late INa in Cardiac Aging

  2026-09-18

  GS967 is a cardiac late sodium current inhibitor for dissecting how pathological Na+ influx links electrical instability with impaired relaxation. This article translates Nav1.5 Ser571 aging research into practical assay decisions for electrophysiology, calcium handling, and arrhythmia prevention research.

• Ceruletide Workflows for Pancreatic Fibrosis

  2026-09-17

  Ceruletide, also called Caerulein, provides a controllable CCK-receptor stimulus for pancreatic injury, secretion, fibrosis, and gastrointestinal motility experiments. This practical workflow connects reagent handling with MFGE8–ANXA1–SMAD2/3 research while emphasizing assay controls, formulation stability, and translational limits.

8029 records 1/536 page Next 12345 下5页 Last page